Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current


HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Lowers Price Target to $50

Author: Benzinga Newsdesk | June 23, 2022 06:13am
HC Wainwright & Co. analyst Raghuram Selvaraju maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and lowers the price target from $56 to $50.

Posted In: RAPT